vs
GENCOR INDUSTRIES INC（GENC）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
GENCOR INDUSTRIES INC的季度营收约是STANDARD BIOTOOLS INC.的1.2倍（$23.6M vs $19.6M），GENCOR INDUSTRIES INC净利率更高（14.6% vs -177.4%，领先192.0%），STANDARD BIOTOOLS INC.同比增速更快（-11.5% vs -25.0%），GENCOR INDUSTRIES INC自由现金流更多（$10.1M vs $-23.1M），过去两年STANDARD BIOTOOLS INC.的营收复合增速更高（-12.2% vs -23.9%）
Gencor Industries Inc是一家重型基建设备制造商，主打沥青生产装置、热力燃烧系统及配套道路施工机械，主要服务北美及全球建筑市场，客户涵盖公共基建项目方和私营建筑运营商。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
GENC vs LAB — 直观对比
营收规模更大
GENC
是对方的1.2倍
$19.6M
营收增速更快
LAB
高出13.5%
-25.0%
净利率更高
GENC
高出192.0%
-177.4%
自由现金流更多
GENC
多$33.2M
$-23.1M
两年增速更快
LAB
近两年复合增速
-23.9%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.6M | $19.6M |
| 净利润 | $3.4M | $-34.7M |
| 毛利率 | 28.7% | 48.5% |
| 营业利润率 | 13.2% | -168.5% |
| 净利率 | 14.6% | -177.4% |
| 营收同比 | -25.0% | -11.5% |
| 净利润同比 | -9.8% | -28.8% |
| 每股收益（稀释后） | $0.23 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GENCLAB
| Q4 25 | $23.6M | — | ||
| Q3 25 | $18.8M | $19.6M | ||
| Q2 25 | $27.0M | $21.8M | ||
| Q1 25 | $38.2M | $40.8M | ||
| Q4 24 | $31.4M | — | ||
| Q3 24 | $20.9M | $22.1M | ||
| Q2 24 | $25.6M | $22.5M | ||
| Q1 24 | $40.7M | $45.5M |
净利润GENCLAB
| Q4 25 | $3.4M | — | ||
| Q3 25 | $1.9M | $-34.7M | ||
| Q2 25 | $3.8M | $-33.5M | ||
| Q1 25 | $6.1M | $-26.0M | ||
| Q4 24 | $3.8M | — | ||
| Q3 24 | $1.5M | $-26.9M | ||
| Q2 24 | $2.6M | $-45.7M | ||
| Q1 24 | $6.2M | $-32.2M |
毛利率GENCLAB
| Q4 25 | 28.7% | — | ||
| Q3 25 | 24.2% | 48.5% | ||
| Q2 25 | 26.5% | 48.8% | ||
| Q1 25 | 29.7% | 48.4% | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 25.6% | 54.9% | ||
| Q2 24 | 23.9% | 46.1% | ||
| Q1 24 | 30.3% | 53.1% |
营业利润率GENCLAB
| Q4 25 | 13.2% | — | ||
| Q3 25 | -1.2% | -168.5% | ||
| Q2 25 | 11.6% | -118.1% | ||
| Q1 25 | 17.0% | -80.8% | ||
| Q4 24 | 14.7% | — | ||
| Q3 24 | 5.9% | -120.9% | ||
| Q2 24 | 7.8% | -134.5% | ||
| Q1 24 | 17.4% | -132.2% |
净利率GENCLAB
| Q4 25 | 14.6% | — | ||
| Q3 25 | 10.2% | -177.4% | ||
| Q2 25 | 14.2% | -153.7% | ||
| Q1 25 | 16.0% | -63.8% | ||
| Q4 24 | 12.1% | — | ||
| Q3 24 | 6.9% | -122.0% | ||
| Q2 24 | 10.0% | -203.3% | ||
| Q1 24 | 15.3% | -70.6% |
每股收益（稀释后）GENCLAB
| Q4 25 | $0.23 | — | ||
| Q3 25 | $0.13 | $-0.09 | ||
| Q2 25 | $0.26 | $-0.09 | ||
| Q1 25 | $0.42 | $-0.07 | ||
| Q4 24 | $0.26 | — | ||
| Q3 24 | $0.10 | $-0.07 | ||
| Q2 24 | $0.17 | $-0.12 | ||
| Q1 24 | $0.42 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $147.7M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $215.2M | $399.7M |
| 总资产 | $228.9M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GENCLAB
| Q4 25 | $147.7M | — | ||
| Q3 25 | $136.3M | $129.4M | ||
| Q2 25 | $136.0M | $158.6M | ||
| Q1 25 | $143.7M | $150.9M | ||
| Q4 24 | $130.1M | — | ||
| Q3 24 | $115.4M | $210.6M | ||
| Q2 24 | $116.6M | $269.8M | ||
| Q1 24 | $117.1M | $287.1M |
总债务GENCLAB
| Q4 25 | — | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益GENCLAB
| Q4 25 | $215.2M | — | ||
| Q3 25 | $211.8M | $399.7M | ||
| Q2 25 | $209.9M | $424.5M | ||
| Q1 25 | $206.1M | $454.6M | ||
| Q4 24 | $200.0M | — | ||
| Q3 24 | $196.1M | $489.3M | ||
| Q2 24 | $194.7M | $510.3M | ||
| Q1 24 | $192.1M | $577.3M |
总资产GENCLAB
| Q4 25 | $228.9M | — | ||
| Q3 25 | $222.6M | $539.6M | ||
| Q2 25 | $220.2M | $557.0M | ||
| Q1 25 | $223.9M | $579.6M | ||
| Q4 24 | $218.2M | — | ||
| Q3 24 | $208.1M | $681.5M | ||
| Q2 24 | $201.8M | $708.7M | ||
| Q1 24 | $206.0M | $777.7M |
负债/权益比GENCLAB
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.1M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $10.1M | $-23.1M |
| 自由现金流率自由现金流/营收 | 43.0% | -118.1% |
| 资本支出强度资本支出/营收 | 4.1% | 4.5% |
| 现金转化率经营现金流/净利润 | 3.23× | — |
| 过去12个月自由现金流最近4个季度 | $-3.2M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流GENCLAB
| Q4 25 | $11.1M | — | ||
| Q3 25 | $-275.0K | $-22.2M | ||
| Q2 25 | $-23.9M | $-20.7M | ||
| Q1 25 | $12.4M | $-30.3M | ||
| Q4 24 | $14.8M | — | ||
| Q3 24 | $-3.2M | $-27.9M | ||
| Q2 24 | $-1.0M | $-39.0M | ||
| Q1 24 | $11.7M | $-62.5M |
自由现金流GENCLAB
| Q4 25 | $10.1M | — | ||
| Q3 25 | $-1.3M | $-23.1M | ||
| Q2 25 | $-24.4M | $-22.6M | ||
| Q1 25 | $12.3M | $-35.3M | ||
| Q4 24 | $14.5M | — | ||
| Q3 24 | $-3.3M | $-30.1M | ||
| Q2 24 | $-1.4M | $-41.0M | ||
| Q1 24 | $11.7M | $-63.3M |
自由现金流率GENCLAB
| Q4 25 | 43.0% | — | ||
| Q3 25 | -6.8% | -118.1% | ||
| Q2 25 | -90.4% | -103.6% | ||
| Q1 25 | 32.2% | -86.6% | ||
| Q4 24 | 46.1% | — | ||
| Q3 24 | -15.8% | -136.4% | ||
| Q2 24 | -5.6% | -182.2% | ||
| Q1 24 | 28.7% | -138.9% |
资本支出强度GENCLAB
| Q4 25 | 4.1% | — | ||
| Q3 25 | 5.4% | 4.5% | ||
| Q2 25 | 1.8% | 8.7% | ||
| Q1 25 | 0.4% | 12.4% | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 0.4% | 10.2% | ||
| Q2 24 | 1.5% | 8.6% | ||
| Q1 24 | 0.0% | 1.7% |
现金转化率GENCLAB
| Q4 25 | 3.23× | — | ||
| Q3 25 | -0.14× | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | 2.04× | — | ||
| Q4 24 | 3.88× | — | ||
| Q3 24 | -2.22× | — | ||
| Q2 24 | -0.41× | — | ||
| Q1 24 | 1.87× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GENC
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
